Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A5SE
|
|||
| Former ID |
DAP001444
|
|||
| Drug Name |
Febuxostat
|
|||
| Synonyms |
Adenuric; TEI; Uloric; Febuxostat [USAN]; S1547; TMX 67; Tei 6720; TMX-67; Tei-6720; Uloric (TN); Febuxostat (JAN/USAN/INN); TMX-67, Adenuric, Uloric, Febuxostat; 111GE013; 2-(3-CYANO-4-ISOBUTOXY-PHENYL)-4-METHYL-5-THIAZOLE-CARBOXYLIC ACID; 2-(3-Cyano-4-(2-methylpropoxy)phenyl)-4-methylthiazole-5-carboxylic acid;2-(3-Cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid; 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hyperuricaemia [ICD-11: 5C55.Y] | Approved | [1], [2] | |
| Company |
Takeda
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H16N2O3S
|
|||
| Canonical SMILES |
CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O
|
|||
| InChI |
1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20)
|
|||
| InChIKey |
BQSJTQLCZDPROO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 144060-53-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
827254, 4484625, 7848269, 7890737, 10243499, 12014717, 14899120, 29311812, 46506708, 50064429, 53197612, 57344764, 92719385, 93307960, 99431926, 103765728, 104142020, 104253203, 104381153, 118047349, 119526879, 121362144, 124757329, 124893781, 125001903, 125164133, 125645402, 126620851, 126652673, 126667078, 127554532, 134338644, 135089359, 135565727, 135692175, 135697551, 135723459, 136367945, 136920430, 137171680, 141631602, 144075735, 144115972, 144206555, 151981114, 152227348, 152258563, 152344198, 160647398, 160813538
|
|||
| ChEBI ID |
CHEBI:31596
|
|||
| ADReCS Drug ID | BADD_D00870 | |||
| SuperDrug ATC ID |
M04AA03
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Xanthine dehydrogenase/oxidase (XDH) | Target Info | Inhibitor | [2], [3] |
| BioCyc | Purine nucleotides degradation | |||
| Urate biosynthesis/inosine 5'-phosphate degradation | ||||
| Guanosine nucleotides degradation | ||||
| Adenosine nucleotides degradation | ||||
| Retinoate biosynthesis II | ||||
| KEGG Pathway | Purine metabolism | |||
| Caffeine metabolism | ||||
| Drug metabolism - other enzymes | ||||
| Metabolic pathways | ||||
| Peroxisome | ||||
| Panther Pathway | Adenine and hypoxanthine salvage pathway | |||
| Purine metabolism | ||||
| Pathwhiz Pathway | Caffeine Metabolism | |||
| Purine Metabolism | ||||
| Reactome | Purine catabolism | |||
| WikiPathways | Oxidative Stress | |||
| Effects of Nitric Oxide | ||||
| Metabolism of nucleotides | ||||
| Selenium Micronutrient Network | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6817). | |||
| REF 2 | Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. | |||
| REF 3 | Clinical pipeline report, company report or official report of Takeda (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.